Vetbiz

Wugen, Inc. is a clinical-stage biotechnology company based in Saint Louis, Missouri, specializing in the development of off-the-shelf cellular therapies for cancer. Their innovative CAR-T platform focuses on creating allogeneic therapies derived from healthy donors, targeting specific leukemias and autoimmune conditions. With a robust pipeline, Wugen has advanced its lead therapy, WU-CART-007, into pivotal trials and continues to support the ongoing development of its therapies through clinical data presentations and strategic leadership appointments. The company's commitment to engineering the next generation of cancer treatments positions it as a key player in the biotechnology sector. Generated from the website